Genome-edited safe and immune-evasive human pluripotent cells: Potential solution for allogeneic therapies

Area of Science:

• Regenerative Medicine
• Immunology
• Stem Cell Biology

Background:

• Allogeneic transplantation faces challenges due to immune rejection.
• Controlling transplanted cell proliferation is crucial for safety.
• Developing immune-evasive stem cells is key for therapeutic success.

Purpose of the Study:

• To evaluate the efficacy and safety of engineered SafeCell-AlloAccept (SC-AlloAccept) human embryonic stem cells.
• To assess the potential for generating allogeneic tissues in an immunocompetent, humanized mouse model.
• To determine the long-term engraftment and immune response to SC-AlloAccept-derived tissues.

Main Methods:

• Utilized a humanized immune system mouse model.
• Generated allogeneic tissues from SC-AlloAccept embryonic stem cells.
• Administered pro-drug ganciclovir to control cell proliferation via the SafeCell kill-switch.

Main Results:

• Successful generation of diverse allogeneic tissues from SC-AlloAccept cells in immunocompetent mice.
• Controlled tissue growth and dormancy achieved using the SafeCell kill-switch.
• SC-AlloAccept grafts demonstrated survival for up to 5 months, indicating long-term engraftment potential.
• No impact on immune response to subsequent transplants after prior sensitization or engraftment of immune-evasive tissue.

Conclusions:

• SC-AlloAccept human cells are validated for transplantation applications.
• Engineered stem cells enhance the safety and efficacy of regenerative therapies.
• This technology holds promise for overcoming immune barriers in stem cell transplantation.